The consensus report advises a patient-focused approach to selecting the suitable drug treatments for hyperglycemia [84]: For patients with chronic renal failure, the usage of an SGLT2 or GLP-1 RA inhibitor with confirmed CVD advantage is recommended regardless of the glycated hemoglobin level. This evidence concerns the gene GCG and chronic kidney disease.